Floatz logo

Cytosin-Arabinosid

Indolent B-cell Non-Hodgkin Lymphoma (iNHL)

GenmabPhase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Indolent B-cell Non-Hodgkin Lymphoma (iNHL) cohort.

Asset / SponsorPhaseRating
Eloxatin
Reid Merryman, MD
Phase 2B
Epcoritamab
Genmab
Phase 1/2CCC

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →